Biomarker-driven management strategies for peripheral T cell lymphoma

Erin Mulvey and Jia Ruan*

Abstract
Peripheral T cell lymphomas are heterogeneous diseases which remain treatment challenges. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven by distinct cells of origins and molecular pathways. The discovery and clinical application of molecular biomarkers in PTCL subtypes has the potential to transform personalized care for patients with PTCL in diagnosis, prognosis, and therapy. Targeting CD30+ PTCL with the antibody-drug conjugate brentuximab vedotin in the relapsed setting and in combination with chemotherapy in the frontline setting has improved patient survivals. Epigenetic modifying agents, including HDAC inhibitors and hypomethylating agents, have demonstrated broad clinical efficacy and durability and are in clinical development for combination strategies for both relapsed and frontline settings. Wide-ranging novel agents targeting critical intracellular pathways and tumor microenvironment are in active exploration to define clinical activities. This review summarizes PTCL-specific biomarkers which are increasingly incorporated in clinical practice to guide precision diagnosis and personalized treatment.

Keywords: CD30-positive peripheral T cell lymphoma (PTCL), Nodal PTCL with T follicular helper (TFH) phenotype, Epigenetic targeting, HDAC inhibitors, Hypomethylating agents, Tumor microenvironment

Introduction
Peripheral T cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas (NHL) derived from mature T/NK cells, encompassing 5–10% NHL in Western countries with a higher incidence of 15–20% in Asia and South America [1, 2]. Despite divergent cells of origin and mechanisms of lymphomagenesis, management of PTCL has historically followed the treatment framework for aggressive B cell NHL, in part due to lack of understanding of subtype-specific disease pathogenesis, as well as difficulty of conducting dedicated prospective treatment studies. Although generally not curative with the exception of ALK+ ALCL, cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) is the most commonly prescribed initial treatment for systemic PTCL. While autologous stem cell transplant may extend progression-free survival (PFS) for some patients, relapse remains common. Recent advances in the molecular and genetic bases of PTCL biology, as well as emergence of targeted therapeutic agents, have made it possible to envision personalized therapeutic progress.

Biomarker-driven classification of PTCL
There are over 30 different subtypes of peripheral T cell lymphoma in the 2016 WHO classification of lymphoid malignancies. The most prevalent nodal T cell lymphomas are peripheral T cell lymphoma, not otherwise specified (PTCL-NOS); nodal T cell lymphoma with T follicular helper (TFH) phenotype which includes angioimmunoblastic T cell lymphoma (AITL); and systemic anaplastic large cell lymphoma (sALCL). Less common subtypes include extranodal NK/T cell lymphoma, nasal type (ENKTL), adult T cell lymphoma/leukemia (ATLL), enteropathy-associated T cell lymphoma (EATL), hepatosplenic T cell lymphoma (HSTL),
of STAT3 due to rearrangements of ALK tyrosine kinase or activating mutations in the JAK/STAT pathway.

**Nodal PTCL with T follicular helper phenotype**

The 2016 WHO revision brings together T cell lymphoma subtypes including angioimmunoblastic T cell lymphoma, follicular T cell lymphoma (FTCL), and PTCL with T follicular phenotype under the provisional entity of nodal PTCL with TFH phenotype, which shared TFH-related antigens and recurrent genetic abnormalities. AITL is one of the more common PTCLs encountered in Western countries, accounting for ~ 28% PTCL in Europe, with lower incidence in North America and Asia (~ 15%) [7]. Patients typically present with advanced-stage disease and symptoms of a systemic illness such as rash, fever, and malaise. AITL can also manifest with immunologic abnormalities such as polyclonal hypergammaglobulinemia or autoimmunity cytopenias. The histology of AITL is characterized by a polymorphous infiltrate of immune cells with a prominent proliferation of high endothelial venules. The tumor cells express follicular T helper cell markers including CD10, CXCL13, PD-1, BCL6, and ICOS. Molecular studies show that T cell receptor genes are rearranged in 75 to 90% of cases, while immunoglobulin heavy chains may be rearranged in up to 25% due to expansion of Epstein-Barr virus (EBV)-associated immunoblastic B cell clones. Gene expression profiling demonstrates a molecular signature typical of follicular helper T cell origin [8, 9], with recurrent driver mutations in TET2, IDH2, DNMT3A, and RHOA, which are implicated in epigenetic regulation.

**Extranodal natural killer/T cell lymphoma, nasal type**

ENKTL is most common in Asia and South America, where EBV infection is endemic. Virtually, all cases contain EBV-encoded small nuclear RNAs (EBERS) [2, 10]. Clinical presentation is notable for mid-facial extranodal lymphoma associated with vascular invasion and necrosis. The immunophenotype of ENKTL is similar to that of natural killer cells which express CD2, CD56, and cytotoxic granule proteins such as granzyme B, TIA-1, and perforin, and lack surface T cell receptor (TCR). There is no typical diagnostic cytogenetic change in ENKTL.

**Adult T cell leukemia-lymphoma**

ATLL is a peripheral T cell lymphoma subtype associated with infection by human T cell lymphotropic virus type 1 (HTLV-1) of CD4 cells in endemic areas such as southern Japan and the Caribbean basin [11]. The long-term risk of developing ATLL following HTLV-I infection has been estimated to be 4 to 5%, usually after a latency period of several decades.
Several clinical variants of ATLL have been described, including acute, lymphomatous, chronic, and smoldering. Peripheral blood smears from leukemia patients exhibit bizarre hyperlobated nuclei known as “clover leaf” or “flower cells.” For immunophenotype, the origin of the malignant cell in ATLL is an HTLV-I-infected memory CD4+ T lymphocyte which expresses CD2, CD3, CD4, and CD25 in most cases. CD52 is often expressed. Genetic sequencing showed somatic mutations in RH0A and TET2, loss-of-function mutations in TP53, and overexpression of PD-L1 [12].

Biomarker-driven therapeutic strategies in R/R PTCL

In addition to contribution to classification and diagnosis of PTCL subtypes, biomarkers provide critical insights into the pathogenic pathways and biological rationale for novel therapeutic intervention (Fig. 1, Tables 1, 2, 3, and 4).

Targeting cell surface receptors

**CD30**

CD30 is a tumor necrosis factor (TNF) receptor family transmembrane receptor with restricted expression in activated T and B cells in normal lymphoid tissues [13]. Across PTCL subtypes, systemic ALCLs universally express CD30 in membrane and golgi patterns, while approximately 50% of non-ALCL subtypes, including PTCL, NOS, AITL, ENKTL, ATLL, EATL, and HSTL, express CD30 at variable levels. CD30 expression in PTCL suggests a CD30-mediated pathogenic mechanism for potential therapeutic targeting with brentuximab vedotin (BV), an antibody-drug conjugate that combines cytotoxic monomethylauristatin E (MMAE) with an anti-CD30 antibody [14]. The level of CD30 expression may not always be predictive of response to BV due in part to tumor heterogeneity, variation in detection and reporting of CD30 expression, and proposed secondary mechanisms of action. Single-agent BV given at 1.8 mg/kg intravenously every 3 weeks for up to 16 cycles in 58 patients with relapsed or refractory (R/R) sALCL showed overall response rate (ORR) of 86% with 57% complete response (CR) in a pivotal phase 2 study, leading to approval in the USA, EU, and Japan for R/R sALCL [15]. Responses in sALCL appear to be durable: 5-year overall survival (OS) and progression-free survival (PFS) were 79% and 57%, respectively, in patients who achieved a CR. In patients who did not achieve a CR, the 5-year OS was 25% [15]. Grade 3 or 4 adverse events (AEs) experienced by ≥ 10% of patients were neutropenia (21%), thrombocytopenia (14%), and peripheral sensory neuropathy (12%). Overall, treatment was well tolerated. In non-ALCL, single-agent BV showed clinical antitumor activity in AITL and PTCL-NOS, with ORR of 41% (including 54% ORR in AITL with a median PFS of 6.7 months), although responses did not correlate with CD30 expression [16]. These results with single-agent BV paved the way for clinical development of BV-containing combinations in both relapsed and frontline settings.

**CD52**

CD52 is a glycosylphosphatidylinositol (GPI) anchored low molecular weight glycoprotein (21–28 kDa) expressed on the surface of B and T lymphocytes, natural killer cells, monocytes, macrophages, and some dendritic cells [17]. PTCL subtypes such as PTCL/NOS, AITL, ATLL, HSTL, and T-PLL were shown to have high frequency of CD52 expression (> 90%) by flow cytometry and IHC analysis, while CD52 expression was low in ALCL and ENT/NKCL [18, 19]. Although the variable and differential CD52 expression in T cell lymphoma tumor cells implies a rational role for anti-CD52 mAb alemtuzumab in the treatment of PTCL, persistent expression of CD52 by the background normal T- and B cell infiltrate limits therapeutic window of anti-CD52 therapy due to potential immunosuppression, including increased risk of viral and other opportunistic infections [20].

Single-agent alemtuzumab has established treatment efficacy in T cell prolymphocytic leukemia (T-PLL). Phase I/II and retrospective studies have indicated response rates of up to 75% in patients with previously untreated disease, although relapse remains nearly universal with mOS of < 2 years. When given three times weekly at 3, 10, and 30 mg IV during week one, followed by 30 mg three times a week for up to 16 weeks, response rate was over 90% in 41 previously untreated T-PLL patients with 81% achieving CRs [21]. Prophylaxis against pneumocystis jiroveci (PJP) and herpes viruses together with regular monitoring for CMV reactivation are recommended to minimize the risk for serious infections [22].

**CCR4**

CC chemokine receptor 4 (CCR4) promotes memory T cell homing to peripheral tissues and is preferentially expressed by Th2 and regulatory T cell subsets [24]. In addition to expression in most CD4+CD25+ ATLL, CCR4 is expressed in approximately 30–65% of PTCL tumor cells, including high expression (~ 65%) in ALK-negative ALCL, variable expression (30–40%) in PTCL/NOS, AITL, and transformed MF, while rarely expressed in ENKTL or ALK-positive ALCL [25]. Mogamulizumab (KW-0761) is a defucosylated, humanized, IgG1 monclonal antibody directed against CCR4 that has direct cytotoxic effect on CCR4-positive lymphoma cells via ADCC, as well as immunomodulatory potential by...
depletion of regulatory T cells to enhance anti-tumor immunity. Mogamulizumab is approved in Japan for R/R CCR4+ ATLL and CTCL and has been approved in the USA for R/R MF and Sezary syndrome. In 28 Japanese patients with CCR4+ R/R ATLL treated with mogamulizumab at 1.0 mg/kg intravenously once weekly for 8 weeks demonstrated ORR of 50% with 30% CR, and median PFS and OS of 5.2 and 13.7 months, respectively [26]. The most common AEs were hematologic events, pyrexia, and skin reactions, all of which were reversible and manageable.

Targeting the epigenome
Emerging genetic studies with gene expression profiling (GEP) and next-generation sequencing (NGS) have shown recurrent mutations in epigenetic regulators which contribute to lymphomagenesis and may represent the target of tailored therapies such as epigenetic modifiers [2].

HDAC inhibitors
In preclinical studies using TCL cell lines, HDAC inhibitors were shown to induce cell-cycle arrest, apoptosis, and DNA damage and modulate a number of
intracellular pathways [28]. Vorinostat, a pan HDAC, was the first drug of its class to be approved by the FDA in 2006 for the treatment of cutaneous T cell lymphoma. A single-arm open-label phase II trial enrolled 74 patients with stage IB or greater CTCL who had failed 2 or more lines of systemic therapy including bexarotene. Patients were treated with oral vorinostat at 300 mg daily or 300 mg 5 days a week and demonstrated favorable responses and an acceptable safety profile: ORR 30% and a median time to tumor progression 202 days [29]. This approval ushered in a still ongoing period of research and development of epigenetic therapy, particularly in TCL.

Romidepsin is a bicyclic class 1 selective HDAC inhibitor approved by the FDA for treatment in patients with R/R PTCL who have failed at least one prior systemic therapy. In a pivotal phase 2 study, 130 patients received romidepsin at 14 mg/m² on days 1, 8, and 15 every 28-day cycle, which showed ORR of 25% including 15% CR/unconfirmed CR (CRu), with durable median duration of response (DOR) of 28 months in responders [30, 31]. Adverse events were manageable and consistent with other HDAC inhibitors, with thrombocytopenia (24%), neutropenia (20%), and infections (all types, 19%) representing the most common grade ≥ 3 AEs. Given the promising results of this study, romidepsin has also been combined with other agents, such as lenalidomide [32], carfilzomib [33], or pralatrexate [34], in attempts to improve efficacy. A phase I/II trial, which included 11 patients with R/R PTCL, showed an ORR of 50% to the doublet of romidepsin given at MTD of 14 mg/m² IV on days 1, 8, and 15 and lenalidomide 25 mg orally on days 1–21 of 28-day cycles [32]. Romidepsin has additionally been combined with lenalidomide and carfilzomib as a triplet in a phase Ib/IIa study that included 16 patients with R/R PTCL. MTD was defined as romidepsin 8 mg/m² days 1 and 8, lenalidomide 15 mg days 1–15, and carfilzomib 36 mg/m² days 1 and 8, every 21-day cycle. The triplet demonstrated a 50% ORR with 30% CR, which seemed to be enriched among patients with AITL (4/5 patients) [33]. A phase I trial combining romidepsin 15 mg/m² and pralatrexate 25 mg/m² in 18 patients with R/R PTCL showed ORR of 71%, which has led to an ongoing phase II trial (NCT01947140) in PTCL [34].

Belinostat, a hydroxamic acid-derived pan-HDAC inhibitor, has also been approved by the FDA in 2014 based on the results of the pivotal phase 2 BELIEF trial [35]. A total of 129 patients with R/R PTCL were treated with 1000 mg/m² belinostat on days 1–5 in 21-day cycles. The ORR was 25.8% including 10.8% CRs. The ORR was 23% in patients with PTCL-NOS, 46% in patients with AITL, and 15% in patients with ALK- ALC. The median ORR was 13.6 months, and median PFS and OS were 1.6 and 7.9 months, respectively. The most common grade 3 to 4 adverse events were anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), and neutropenia (6.2%).

The oral class I/II HDAC inhibitor chidamide has been studied in 83 R/R PTCL patients in China in a phase II study, which included patients with PTCL NOS (34%), ALC. (22%), ENKTL, nasal type (20%), or AITL (13%). Patients received chidamide 30 mg orally twice per week. The ORR was 28% including 14% with CR/CRu. Median PFS and OS were 2.1 and 21.4 months, respectively. AITL patients tended to have higher ORR (50%) and CR/CRu rate (40%), as well as more durable responses to chidamide treatment, with a manageable toxicity profile [36].

### Hypomethylating agents

5-Azacitidine (5-AZA) has shown efficacy in myeloid neoplasms where response rates appear to correlate with TET2, IDH1/2, and/or DNMT3A mutations which regulate DNA methylation levels [37]. It was hypothesized that hypomethylating agents could be effective in TFH-derived PTCL given the abundance of recurrent TET2, DNMT3A, and IDH2 mutations. A retrospective French LYS2 cohort study reported clinical outcome of 12 patients with R/R AITL (41% with associated myeloid neoplasms) treated with subcutaneous daily injection of 75 mg/m² 5-AZA for 7 consecutive days every 28-day cycle. The treatment appeared to be promising: ORR was 75% including 50% CR, median PFS was 15 months, and median OS was 21 months. Molecular studies revealed TET2 mutation in 100% of patients, 33% with DNMT3A mutations, 41% with RHOA mutations, and one patient with IDH2R172 mutation [38]. Currently, a global phase 3 study is ongoing to prospectively compare the efficacy and safety of oral azacitidine (CC486) to the investigator’s single-agent choice of either romidepsin, bendamustine, or gemcitabine in patients with R/R AITL (NCT03593018). Azacitadine has also been studied in combination with romidepsin in a multicenter phase I trial. Azacitadine was given orally at a MTD of 300 mg on days 1 to 14 with romipresin 14 mg/m² given IV on days 8, 15, and 22 on a 35-day cycle in 31 patients with R/R lymphomas. This pair was particularly effective in PTCL, where it produced ORR of 73% with 55% CR and was well tolerated [39]. A phase II study with this combination is maturing to confirm the efficacy data in PTCL.

### Targeting tumor microenvironment

**PD1/PD-L1**

PD1 is a type I membrane protein that belongs to the immunoglobulin superfamily. It is a member of the extended CD28/CTLA-4 family of immune checkpoint that guards against autoimmunity by downregulating the immune system and promoting self-tolerance [40]. PD-1 is expressed on the surface of activated T cells, B cells, and macrophages and negatively regulates immune responses broadly. PD1 binds two ligands, PD-L1 and PD-L2. In
PTCL, PD-1 expression was detected in atypical T lymphoma cells in the majority of AITL (> 90%), to a lesser extent in PTCL/NOS (30–60%), and rarely in other subtypes [41]. In AITL, both PD1 and CXCL13, a chemokine promoting B cell migration and survival in lymph node, showed a similar expression frequency highlighting follicular helper T cells (TFH) [42], which may share additional TFH markers including CD10, BCL6, and ICOS [43]. In NKTCL, PD-L1 expression in NK/T cell lymphoma cells ranged from 56 to 93% in various studies, while PD-1 level was low [44]. In ATLL, PD-L1 amplification was shown as a strong genetic predictor in both aggressive and indolent ATLL [45]. Anti-PD1 immune checkpoint blockade strategy has generated mixed results in PTCL to date due to the complexity that malignant T cell lymphoma cells can express PD-1. In such instances, immune checkpoint blockade has the potential to accelerate tumor growth in tumor cells with high PD-1 expression, as proposed in murine studies [46]. ATLL patients treated with nivolumab developed rapid disease progression after 1 cycle of nivolumab treatment [47], cautioning against the use of immune checkpoint blockade in ATLL without further understanding the complex mechanism of immune evasion and activation. In other subtypes, responses have been mixed. In patients with R/R T cell lymphoma, single-agent nivolumab produced ORR of 40% [48], while PD1 blockade with pembrolizumab showed high efficacy (100% ORR, 71% CR) in a case series of 7 R/R EBV–associated NK and T cell lymphoma [49]. A phase II multicenter trial of patients with R/R PTCL who were treated with pembrolizumab was halted early after a preplanned interim futility analysis [49]. Nevertheless, several trials are ongoing to further explore the efficacy of PD-1 blockade in PTCL. Pembrolizumab is being added to romidepsin (NCT03278782) and pralatrexate (NCT03598998) in ongoing phase I/II trials in patients with R/R PTCL. Pembrolizumab is also being combined with pralatrexate and the epigenic modifier decitabine in an ongoing phase I trial (NCT03240211). The PD-1 monoclonal antibody durvalumab is being studied alone and in combination with lenalidomide in patients with R/R PTCL and CTCL (NCT03011814) as well as in combination with pralatrexate, romidepsin, and/or azacitidine (NCT03161223). The novel PD-1 monoclonal antibodies avelumab (NCT03046953) and tislelizumab (NCT03493451) are being evaluated in R/R PTCL and R/R mature NK and T cell lymphomas, respectively.

**Immunomodulatory agents**

Lenalidomide is a well-established immunomodulatory agent in B cell NHL and multiple myeloma, which has shown modest single-agent activity in PTCL in phase 2 studies. The EXPECT trial with lenalidomide 25 mg given once daily on days 1–21 of 28-day cycle showed ORR of 22% with 11% CR/Cru in various R/R PTCL subtypes, including ORR 31% with CR/Cru 15% in AITL [50]. Overall, 35% of patients experienced at least 1 AE that lead to study dose interruption or reduction, most commonly neutropenia or thrombocytopenia. Lenalidomide given at 25 mg daily continuously in a phase 2 study of Japanese patients with R/R ATLL showed ORR of 42% with 19% CR/Cru, and median PFS and OS at 3.8 and 20.3 months, respectively. Toxicities were manageable in this population with all serious AEs resolving or resolved by the end-of-study assessment [51].

**Targeting signaling and proliferation pathways**

**ALK**

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase known to be oncogenically activated in a subset of ALCL. Crizotinib is an ALK-ROS1-MET small molecule inhibitor which showed a high response rate (ORR 90%) in the Children’s Oncology Group study of 26 ALK+ ALCL patients [33, 52]. In this prospective phase I/II trial, patients were treated with crizotinib at 165 mg/m² or 280 mg/m² orally twice daily on days 1–28 of 28-day cycles. CR was observed in 83% (five of six) of ALCL165 and 80% (16 of 20) of ALCL280, with a median duration of therapy of 2.79 and 0.4 years, respectively. A retrospective study of 11 adult patients with R/R ALK+ lymphoma treated with crizotinib 250 mg twice daily until disease progression achieved 90.9% ORR with OS and PFS at 2 years of 72.7% and 63.7%, respectively [53]. Crizotinib-related toxicities were mild and manageable. These studies highlight the important role the ALK pathway plays in these diseases.

**PI3K inhibitors**

Phosphatidylinositol 3-kinase (PI3K) is a lipid kinase that is involved in intracellular signal transduction, with the PI3K-δ and PI3K-γ isoforms preferentially expressed in leukocytes where they modulate both innate and adaptive immune function by mediating pathways important for survival, proliferation, and differentiation [54, 55]. Specifically, inhibition of PI3K-δ and PI3K-γ isoforms blocks mitogenic and survival within tumor cells, disrupts interaction with the tumor microenvironment, and restores antitumor immune responses. The PI3K δ/γ inhibitor duvelisib was evaluated in a phase I dose-escalation trial in 16 patients with R/R PTCL at a MTD of 75 mg twice daily on a 28-day cycle where it resulted in a 50% ORR with 3 CRs. The median PFS was 8.3 months, with activity demonstrated across a number of subtypes [56], and a phase II trial is underway (NCT03372057). Duvelisib is also being studied in combination with romidepsin and bortezomib in a parallel phase I study in patients with PTCL and CTCL. Duvelisib is given at 75 mg twice daily on days 1–28 on 28-day cycles with either romidepsin 10 mg/m² on days 1, 8, and 15 (arm A) or with bortezomib 1
mg/m² on days 1, 4, 8, and 11 (arm B) [56, 57]. These combinations show activity with ORR and CR rates of 55% and 27% for patients with PTCL treated on arm A, and 36% and 21%, respectively, in patients treated on arm B. The median PFS and OS were 8.8 months and 9.1 months for PTCL patients on arm A and 3.5 months and 9.3 months for patients on arm B. Of note, 65% of patients treated on arm A experienced grade 3 or higher adverse events (AEs) with neutropenia (18%) and elevated transaminases (15%) being the most frequent. Among patients treated on arm B, 45% experienced grade 3 or higher AEs with neutropenia (18%) occurring in more than 10% of patients. A phase IB dose-escalation study is being planned to examine the combination of romidepsin with the PI3K α/δ inhibitor copanlisib (NCT04233697). The PI3K-δ inhibitor YY-20394 is being evaluated in an ongoing phase I trial in patients with R/R PTCL (NCT04108325).

**mTOR inhibitors**

Everolimus is an oral agent that inhibits the mammalian target of rapamycin (mTOR) pathway and has been shown to strongly inhibit malignant T cell proliferation in vitro [58]. Single-agent everolimus given at 10 mg daily continuously has been studied in a phase II trial including 16 patients with R/R PTCL with a variety of subtypes, including 4 PTCL-NOS, 2 ALCL, and 1 each had extranodal NK/T cell, AITL, and precursor TLL lymphoma. Everolimus resulted in an ORR of 44% with a median PFS of 8.5 months and an overall survival of 10.2 months. Among responders, the median DOR was 8.5 months [58]. Dose reduction to 5 mg daily was required in 35% of patients.

**Aurora kinase inhibition**

Aurora A kinase (AAK) is a mitotic oncogenic serine/threonine kinase that plays an essential role in progression through the cell cycle during mitosis and has been shown to be upregulated in aggressive lymphomas [59–61]. Alisertib is an oral AAK inhibitor that was studied in the SWOG1108 phase II trial which included 37 patients with R/R PTCL or transformed mycoses fungoides [62]. Patients received alisertib 50 mg twice daily for 7 days every 21-day cycle, resulting in a 30% ORR with 7% CRs, and median PFS and OS of 3 months and 8 months respectively [64]. Consistent with earlier phase I data, myelosuppression was common (in up to 32% of patients) and was the most common reason for dose reductions. The phase III Lumiere trial compared single-agent alisertib to investigator’s choice of single-agent of pralatrexate, gemcitabine, or romidepsin [63]. Alisertib showed similar results with an ORR of 33% with 16% CR, a median PFS of 2.7 months, and a median OS of 9.9 months. Based on preclinical data suggesting synergism [64], alisertib was studied in combination with romidepsin in a phase I trial of R/R aggressive lymphomas including 4 patients with PTCL. While the primary end-point of the study was to demonstrate safety and tolerability, this combination resulted in disappointing results in these heavily pretreated PTCL patients, with no CRs or PRs [65].

**Antifolates**

Pralatrexate, a folate analogue metabolic inhibitor that selectively enters cells through reduced folate carrier type 1 (RFC-1), was studied in the pivotal multicenter phase II PROPEL trial [66]. Patients with R/R PTCL were treated with weekly pralatrexate 30 mg/m² infusions for 6 weeks in 7-week cycles. The response rate among the 109 evaluable patients was 29%, including 12 complete responses (11%) and 20 partial responses (18%), with a median DoR of 10.1 months. Median PFS and OS were 3.5 and 14.5 months, respectively. Pralatrexate received FDA’s approval for R/R PTCL in 2009.

**Therapies available and under investigation to target biomarkers in frontline PTCL**

CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) is the most commonly prescribed initial therapy for PTCL, despite results showing that the majority of PTCL patients have an inferior outcome compared with their B cell counterparts receiving CHOP, with the exception of ALK-positive ALCL. Data from the international T cell project showed that the 5-year OS for PTCL-NOS, AITL, and NK/TCLs was 32% compared with 14% for ATLL. ALK-positive ALCL demonstrated 5-year OS of 70%, compared to 49% with ALK-negative ALCL [1]. There is a paucity of prospective randomized trials comparing alternative chemotherapy combinations with CHOP in frontline setting, given disease rarity and heterogeneity. The German High-Grade Non-Hodgkin Lymphoma Study Group, in a retrospective ad hoc analysis of over 300 patients with PTCL, showed that the addition of etoposide to CHOP (CHOEP) improved the EFS of patients younger than 60 who had ALCL and normal LDH levels. Other subgroups of patients did not appear to significantly benefit from this addition [67]. To date, standard-dose CHOP remains the reference regimen in PTCL treatment. Efforts to improve frontline therapy in PTCL have been focused on several strategies: (1) to improve upon CHOP by incorporating novel agent X into CHOP chemotherapy backbone, whereas X denotes therapeutic targeting of surface biomarkers such as CD30 and CD52, or epigenetic modifiers regulating essential pathogenic pathways involving modification of histone acetylation and methylation; (2) to explore novel combination free of conventional chemotherapy; and (3) to experiment with novel agents for consolidation and maintenance following chemotherapy induction.
Biomarker-driven strategies to improve CHOP-based induction chemotherapy

Targeting CD30-positive PTCL with brentuximab vedotin plus chemotherapy

The feasibility of adding BV to CHOP in first-line setting was evaluated in a phase 1 study with BV 1.8 mg/kg administered either sequentially with standard-dose CHOP (BV × 2 cycles, followed by CHOP × 6 cycles) or in combination with CHP (CHOP without vincristine) for 6 cycles in patients with mostly CD30-expressing ALCCL. Responders received single-agent brentuximab vedotin for 8–10 additional cycles (for a total of 16 cycles) [68]. The ORR was 85% (CR 62%) with sequential treatment, and ORR was 100% (CR 88%) with combination treatment. Safety profile was manageable. Durable remission at 5 years was noted in 50% of patients without subsequent anti-cancer therapy [69]. Based on this encouraging phase 1 data, a global double-blind, randomized phase 3 study (ECHELON-2, NCT01777152) was initiated in 2013 comparing BV-CHP with standard CHOP in untreated CD30-positive PTCL (targeting 75% ALCCL) [70], and randomized 452 patients. BV-CHP was associated with higher CR rate (68% vs 56%, p = 0.0066) and superior survival. Median PFS was 48.2 months in the BV-CHP group, significantly improved compared to 20.8 months in the CHOP group. In addition, BV-CHP reduced the risk of death by 34% compared with CHOP. Adverse events, including febrile neutropenia and peripheral neuropathy, were similar between groups. ECHELON-2 is the first randomized phase 3 study establishing the superiority of BV-CHP over CHOP in untreated CD30-positive PTCL, which led to FDA approval in November 2018 of BV-CHP as frontline therapy for CD30-positive PTCL, which led to FDA approval in November 2018 of BV-CHP as frontline therapy for CD30-positive PTCL. Although the ECHELON-2 study included non-ALCL cases such as PTCL-NOS, AITL, ATLL, and EATL (~30% enrollment, 136 total), their small sample sizes precluded sufficient power analysis.

Targeting CD52-positive PTCL

Given the variable expression of CD52 in PTCL subtypes, a prospective multicenter trial evaluated the feasibility and clinical efficacy of the combination of alemtuzumab with CHOP regimen (CHOP-C) as the primary treatment for 24 patients with peripheral T cell lymphoma (PTCL) that included PTCL/NOS, AITL, ALK-negative ALCCL, and EATL [71]. Patients received 8 CHOP courses, with alemtuzumab given at 30 mg subcutaneously at day 1 prior to CHOP given at standard 21-day cycle. Complete remission (CR) was achieved in 17 (71%) patients, 2-yr OS was estimated at 53% and 2-yr PFS at 48%. Despite promising CR rate, alemtuzumab-containing therapy was accompanied by substantial immunosuppression and infectious complications. Similar findings were noted in more intensive combinations of alemtuzumab plus either CHOP-14 (HOVON) [72] or DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) [73]. Twenty patients were treated on the phase 2 HOVON alemtuzumab-CHOP14 study, which showed ORR of 90%; CR 60%; 2-year OS and EFS at 55% and 27%, respectively; high rates of neutropenic fever (40%); and CMV reactivation (35%), as well as secondary EBV-related lymphoma (15%) [72]. Thirty patients were treated on the phase 1/2 NCI alemtuzumab with DA-EPOCH study. CR was achieved in 17 (57%) patients, and ORR was 83%, with median OS and PFS at 20.2 and 6.6 months, respectively. There were five treatment-related deaths on study due to infectious complications [73]. Phase 3 studies comparing the addition of alemtuzumab to CHOP14 versus CHOP14 alone in younger (ACT-1, NCT00646854) and elderly (ACT-2, NCT00725231) patients could not reach planned sample sizes due to low recruitment, and combined analysis of ACT-1 and ACT-2 studies of 252 patients showed no significant difference in EFS, PFS, and OS, while alemtuzumab-CHOP was associated with more infections.

Targeting epigenetic pathways

HDAC inhibitors Feasibility of HDAC inhibitors with CHOP combination has been evaluated with romidepsin, belinostat, and chidamide in the first-line setting. In the phase 1b/II LYSARC study of romidepsin-CHOP combination, the RP2D for romidepsin was 12 mg/m² on days 1 and 8 of each cycle for 8 cycles. High CR rate (51%) was achieved with 30-month PFS of 41% and 30-month OS of 70.7% [35], which forms the basis for the ongoing phase 3 LYSARC study (NCT01796002) evaluating survival and response with 6 cycles of Ro-CHOP compared to standard CHOP. The outcome of this phase 3 study is maturing and highly awaited, especially with regard to non-ALCL PTCL subtypes including AITL in the context of ECHELON-2 data which enrolled mostly ALCCL patients. The addition of romidepsin to CHOP is also being evaluated in ongoing phase I/II study in young patients with nodal PTCL prior to proceeding with hematopoietic stem cell transplant (NCT02223208).

The combination of belinostat plus CHOP in frontline setting was explored as well, with phase 3 study of Bel-CHOP planned [74]. The oral HDAC inhibitor chidamide was evaluated in a phase 1b/2 study in combination with CHOP in China [75]. Patients received one dose chidamide as the run-in treatment, followed 4 days later by CHOP (6 cycles, each 21 days) with chidamide on days 1, 4, 8, and 11 at MTD of 30 mg. Patients achieving a CR/Cru following induction treatment received consolidation
| Agent | Target | Trial/phase | Subtype | N | ORR (%) | CR (%) | Median DOR (months) | Median PFS (months) | Median OS (months) | AEs |
|-------|--------|------------|---------|---|---------|--------|--------------------|-------------------|-------------------|-----|
| **Frontline** | Brentuximab vedotin + CHOP, “BV-CHP” | Anti-CD30 Ab-drug conjugate | ECHELON-2 multinational phase III [70] BV-CHP vs. CHOP | 226 | 83, 68 | Not reported | 48.2 | Not reached after 3 years follow-up, 34% risk of death reduction | Increased diarrhea, any grade (38% vs 20%) in BV-CHP vs CHOP, other AEs comparable between two cohorts |
| | | | CD30+ PTCL, ALCL 72%, (ALK+22%, ALK− 50%), PTCL-NOS 13%, AITL 13% | | | | | | | |
| | | | Median DOR (months) | | | | | | | |
| | | | Median PFS (months) | | | | | | | |
| | | | Median OS (months) | | | | | | | |
| | | | AEs | | | | | | |
| **Relapsed/ refractory** | Brentuximab vedotin | Anti-CD30 Ab-drug conjugate | Multinational phase II [15] | 58 | 86, 57 | 12.6 | 20, 57% at 5 years | Not reached | 79% at 5 years | Grade ≤ 3 AEs: neutropenia (21%), thrombocytopenia (14%), peripheral sensory neuropathy (12%) |
| | | | CD30+ PTCL, PTCL-NOS 63%, AITL 37% | 35 | 41, 24 | 7.6 | 2.6 | Not reported | | |
| | | | Multinational phase II [16] | | | | | | | |
| Romidepsin | HDAC-1 inhibitor | Multinational phase II [30] | PTCL, PTCL-NOS 53%, AITL 21%, ALCL, ALK− 16% | 130 | 25, 15 | 28 | 4 | 11.3 | Grade ≤ 3 AEs: thrombocytopenia (24%), neutropenia (20%), infections (all types, 19%) |
| Belinostat | Pan-HDAC inhibitor | Multinational phase II [35] | PTCL, PTCL-NOS 64%, ATIL 18%, ALCL, 14% (ALK+ 2%, ALK− 12%), EATL 2%, ENKTL 2%, HSTCL 2% | 129 | 25.8, 10.8 | 13.6 | 1.6 | 7.9 | Grade ≤ 3 AEs: anemia (10.8%), thrombocytopenia (7%), dyspnea (6.2%), neutropenia (6.2%) |
| Chidamide* | HDAC class I/II inhibitor | Chinese phase II [36] | PTCL, PTCL-NOS 35%, ALCL 22% (ALK− 14%, ALK+ 4%, ALK unk. 4%), NKTL 20%, AITL 13% | 79 | 28, 14 | 9.9 | 2.1 | 21.4 | Grade ≤ 3 AEs: thrombocytopenia (22%), leukopenia (13%), neutropenia (11%) |
| Pralaxtrete | Antifolate | PROPEL North American phase II [86] | PTCL | 109 | 29, 11 | 10.5 | 3.5 | 14.5 | Grade ≤ 3 AEs: thrombocytopenia (32%), mucositis (22%), neutropenia (22%), anemia (18%) |
| Mogamulizumab¥ | Anti-CCR4 mAb | Japanese phase II [27] | CCR4+ R/R ATLL, acute 54%, lymphomatous 23%, chronic 23% | 26 | 50, 31 | Not reported | 5.2 | 14.4, 23% at 3 years | All grades: infusion reactions (89%), skin rash (63%, 1 Stevens-Johnson syndrome) Skin rash appears to correlated with response |
| | | | Japanese phase II [86] | 29 | 34, 13.5 | Not reported | 2 | 14.2 | Grade ≤ 3 AEs: lymphopenia (81%), neutropenia (38%), leukopenia (43%) Skin rash (all grades), 51%; grade ≥ 3, 11% |

Licensed by FDA unless otherwise noted

*Approved in China
¥Approved in Japan
| Agent                  | Target                        | Trial/phase                  | Subtype                                                                 | N  | ORR (%) | CR (%) | Median DOR (months) | PFS (months) | OS (months) | AEs                                                                 |
|------------------------|-------------------------------|-----------------------------|--------------------------------------------------------------------------|----|---------|--------|------------------|-------------|------------|---------------------------------------------------------------------|
| Alisertib              | Aurora A kinase inhibitor     | SWOG1108 phase II [62]      | R/R PTCL or transformed MF (IMT)PTCL-NOS 35%, AITL 24%, ATLL 11%        | 37 | 30, 7   | 3      | Not reported      | 8           |            | Gr ≥ 3 AEs: neutropenia (32%), anemia (30%), thrombocytopenia (24%), febrile neutropenia (14%), mucositis (11%), rash (5%) |
|                        |                               | Lumiere phase III [87], alisertib vs. investigator’s choice | R/R PTCL, PTCL-NOS 45%, AITL 22%, ALC 6%, ALK= 5% ALK+ 1%, EATL 2%, ENKTL 1% | 120| 33, 16  | 5      | 2.7             | 9.9         |            | Gr ≥ 3 AEs (alisertib vs. comparator): neutropenia (43% vs 25%), thrombocytopenia (29% vs 27%), anemia (33% vs 11%) |
| Alemtuzumab            | Anti-CD52 mAb                 | European phase II [20]      | R/R PTCL                                                                 | 14 | 36, 21.4|        | Not reported      | Not reported | Not reported | CMV reactivation in 6 pts; Pulmonary aspergillosis in 2 pts; EBV-related hemophagocytosis in 2 pts; 5 treatment-related deaths |
| 5-Azacitidine          | Hypomethylating agent         | Retrospective series [38]   | R/R AITL (1 pt previously untreated), (41% with concomitant myeloid neoplasm) | 12 | 75, 50  |        | 15               | 21          |            | TET2 mutations detected in all 12 patients                           |
| Crizotinib             | ALK ROS1 inhibitor            | Retrospective series [53]   | R/R ALK+ lymphoma, ALCL, ALK+ 82%                                       | 11 | 100, 100|        | Not reported      | Not reported | Not reported | No Gr ≥ 3 AEs                                                                 |
|                        |                               | Phase I/II Children’s Oncology Group [52] | R/R ALK+ ALC. *Pediatric patients (aged 18 months–22 years old) | 26 | 165 mg/m²: 83, 90 280 mg/m²: 83, 36 |        | Not reported      | Not reported | Not reported | Gr ≥ 3 AEs: 165 mg/m² 22%, 280 mg/m² 70%                              |
| Duvelisib              | PI3K δ/γ inhibitor            | Phase I [56]                | R/R PTCL                                                                 | 16 | 50, 19  |        | 4.4             | Not reported |            | Gr ≥ 3 AEs: transaminase increases (40% ALT, 17% AST), maculopapular rash (17%), neutropenia (17%) |
| Everolimus             | mTOR inhibitor                | Phase II [58]               | R/R PTCL + MF,PTCL-NOS 25%, ALC 12.5%, AITL 6% ENKTL 6%                 | 16 | 44      | 8.5    | 4.1             | 10.2        |            | Gr ≥ 3 AEs: hematologic toxicity 37.5%                               |
| Lenalidomide           | Immuno-modulator              | EXPECT, phase VII [50]      | R/R PTCL, AITL 48%, PTCL-NOS 37%, ALC 6%                                | 54 | 22, 11  | 3.6    | 2.5             | Not reported |            | Gr ≥ 3 AEs experienced by 54% 12 treatment-related deaths: acute respiratory distress syndrome dyspnea, lung infiltration, neutropenic sepsis, pneumonia and cerebral ischemia (n = 1 each) |
|                        |                               | ATLL-002 phase II [51]      | R/R ATLL, acute 58%, lymphomatous 27%, chronic 15%                      | 26 | 42, 19  |        | 3.8             | 20.3        |            | Gr ≥ 3 AEs: neutropenia (65%), leukopenia (38%), lymphopenia (38%), neutropenia (23%) |
| Nivolumab              | Anti-PDL-1 mAb                | Phase Ib [48]               | R/R PTCL, AITL 50%, PTCL-NOS 25%, ALC, ALK– 8%                         | 12 | 33, 17  | 3.6    | 1.9             | 7.9         |            | Immune-mediated AEs in 34%; 53.5% required treatment for immune-mediated AE |
|                        |                               | Phase II [47]               | ATLL: 1 acute, 1 lymphomatous, 1 chronic                               | 3  | n/a     |        | n/a             | n/a         |            | All 3 patients developed rapid progression of disease after the 1st dose |
| Pembrolizumab          | Anti-PDL-1 mAb                | Retrospective series [88]   | R/R EBV+ NKTL, failing L-asparaginase                                     | 7  | 100, 71.4|        | Not reported     | Not reported | Not reported | 1 patient (post-alloHSCT) developed grade 2 rash; no other AEs                                                                 |
| Agent                          | Target          | Trial/phase | Subtype                    | N  | ORR (%) | CR (%) | Median DOR (months) | PFS (months) | OS (months) | AEs                                                                 |
|-------------------------------|-----------------|-------------|----------------------------|----|---------|--------|---------------------|--------------|-------------|---------------------------------------------------------------------|
| Phase II [49]                | R/R PTCL        | 18          | 33, 27                     | 2.9| 3.2     | 10.6   | Trial halted early after preplanned interim futility analysis    |
| Romidepsin + lenalidomide     | R/R TCL, 10 CTCL, 11 PTCL | 21          | 50                         | Not reported | 13.5 weeks* | Not reached | Grade ≥ 3 AEs: neutropenia (48%), thrombocytopenia (38%), anemia (33%), electrolyte abnormalities (K, Phos, glucose, Mg (43%) |
| Phase Ib/IIa [33]            | R/R TCL, PTCL-NOS 47%, AITL 21% | 19          | 50, 31                     | 9.8 weeks* | 9.7 weeks* | Not reached | Grade ≥ 3 AEs in ≥ 10% of patients: neutropenia, thrombocytopenia |
| Romidepsin + pralatrexate     | R/R lymphomas, TCL 62%, AITL 21%, ALCL, ALK− 10% | 23          | 71, 40                     | 4.29| 4.4     | 12.4   | Grade 4 AEs: thrombocytopenia (14%), neutropenia (10%), sepsis (7%), fever (3%), and pneumonia (3%) |
| Romidepsin + azacitadine      | R/R lymphomas, TCL 35%, AITL 10%, ATLL 6% | 31          | 32, 23                     | 2.5 TCL: not reached | Not reached | Not reported | Grade ≥ 3 AEs: thrombocytopenia (27%), neutropenia (42%), lymphopenia (42%), hypotension (12%), hyponatremia (8%) |
| Duvelisib + romidepsin + bortezomib | R/R PTCL + CTCL | Arm A: 22Arm B: 14 | Arm A: 55, 27Arm B: 36, 21 | Arm A: 8.8 Arm B: 3.5 | Arm A: 9.1 (all patients) Arm B: 9.3 (all patients) | Not reported | Arm A: 65% with Gr ≥ 3 AEs: increased ALT/AST (15%), neutropenia (18%), hyponatremia (12%) Arm B: 45% with Gr ≥ 3 AEs: neutropenia (18%), 1 pt with Stevens-Johnson syndrome |
| Agent | Trial/phase | Subtype | N | ORR (%) CR (%) | Median PFS (months) | Median OS (months) | AEs |
|-------|-------------|---------|---|----------------|---------------------|--------------------|-----|
| Alemtuzumab | Phase II [23] | T-PLL | 32 | IV route: 91, SubQ route: 33 | 67% at 12 months | 37% at 48 months | IV route: 2 patients with grade 4 hematologic AEs; 2 asymptomatic CMV reactivation; 2 skin reactions | SubQ route: 22% of patients died on treatment |
| Alemtuzumab + CHOP, "CHOP-C" | GITIL phase II [71] | PTCL, PTCL-NOS 58.3%, AITL 25% ALCL, ALK− 12.5% | 24 | 75, 71 | 48% at 2 years | 53% at 2 years | JC viral encephalitis in 1 pt | Invasive aspergillosis in 2 pts PJP in 1 pt | Staphylococcus sepsis in 1 pt |
| CHOP + alemtuzumab followed by ASCT | ACT-1 phase III [89] | CD 52+ PTCL (no ALCL), PTCL-NOS 58%, AITL 21% | 65 | 77, 52 | 37% at 3 years | 52% at 3 years | Grade 4 leukopenia (73% vs 35% in CHOP arm, p = 0.001) | Grade ≥ 3 bacterial/fungal infections and other serious AEs similar in both arms | *After 2 pts developed systemic fungal infections, an amendment tapered ALZ dose from 360 mg (30 mg on days 1 + 2 of each CHOP course) to 120 mg (30 mg on day 1 of CHOP courses 1–4) |
| Alemtuzumab + CHOP-14 | HOVON phase II [72] | CD 52 + PTCL, PTCL-NOS 50%, AITL 30%, subcutaneous panniculitis-like (SPTCL) 15%, EATL 5% | 20 | 90, 60 | 10 | 27 | Neutropenic fever (40%), CMV reactivation (35%), secondary EBV-related lymphoma (15%) |
| Alemtuzumab + DA-EPOCH | NCI phase I/II [73] | CD 52+ PTCL-NOS 35%, AITL 32%, AITL 13%, CGD TCL 6%, epatosplenic TCL 6% | 30 | 833, 57 | 66 | 20.2 | 5 treatment-related deaths: 2 sepsis, 1 cardiac arrest, 1 pneumonia, 1 disseminated toxoplasmosis |
| Romidepsin + CHOP, "Ro-CHOP", LYSARC | LYSAR phase II [90] | PTCL, PTCL-NOS 28%, AITL 22% ALCL, ALK− 11%, EATL 6%, follicular PTCL 6%, AITL 6% | 37 | 69, 51 | 41% at 30 months | 71% at 30 months | Gr ≥ 3 AEs: neutropenia (89%), thrombocytopenia 78%, anemia (43%) | QT prolongation < 480 ms (37%); 480–500 ms (5%) |
| Lenalidomide + CHOP, "len-CHOP" | LYSAR phase II [77] | AITL, pts > 59 years old | 78 | 47,44,43.6 | 42.3% at 2 years | 60.1% at 2 years | 29% discontinuation rate due to toxicities (15 pts) or POD (8 pts) | 4 secondary malignancies | 5 treatment-related deaths (4 infections) |
| Lenalidomide + CHOP, "len-CHOP" | T cell consortium phase II [76] | PTCL, PTCL-NOS 57.5%, AITL 30% ALCL, ALK− 12.5% | 12 | 68,48 | 68% at 1 year | 89% at 1 year | 25% discontinuation rate due to toxicity (6 pts) or POD (4 pts) | 5 deaths: 1 POD, 2 sepsis, 1 cardiac arrest, 1 secondary malignancy (AML) |
| Belinostat + CHOP | Bel-CHOP phase I [74] | PTCL, PTCL-NOS 43%, AITL 39% ALCL, ALK+ 9% ALCL, ALK− 4% | 23 | 89, 72 | Not reported | Not reported | Gr ≥ 3 AEs: neutropenia (26%), anemia (22%), lymphopenia (17%) |
| Pralatrexate alternating with CEOP | T cell Consortium phase II [78] | PTCL, PTCL-NOS 64%, AITL 24% ALCL, ALK− 12% | 33 | 70, 52 | 39% at 2 years | 60% at 2 years | Gr ≥ 3 AEs: anemia (27%), thrombocytopenia (12%), febrile neutropenia (18%), mucositis (18%), sepsis (15%), elevated creatinine (12%), elevated and liver transaminases (12%) |
| Chidamide + CHOP | Phase Ib/II [75] | PTCL, PTCL-NOS 40%, AITL 26.7% ALCL, ALK+ 13.3% ALCL, ALK− 10% | 30 | 821, 46.4 | 14,54.3% at 12 months | Not reached, 100% at 12 months | Gr ≥ 3 AEs: leukopenia (90%), neutropenia (83.3%), lymphopenia (40%), vomiting (13.3%), thrombocytopenia (10%), and febrile neutropenia (10%) |
| Setting          | Agent(s)                             | Study                                                                 | Phase | N  | Treatment                                                                                                                                                                                                 | ClinicalTrials.gov |
|------------------|--------------------------------------|----------------------------------------------------------------------|-------|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|
| **Front-line**   | Romidepsin + CHOEP                    | Young patients with untreated nodal PTCL: a phase I-II study         | I/I   | 110| Phase I: romidepsin dose escalation + CHOP-21, followed by stem cell mobilization and transplantation. Phase II: Ro-CHOP-21 x 3 cycles; if PR or CR, Ro-CHOP-21 continues for 3 additional cycles followed by stem cell mobilization and transplantation. | NCT02223208       |
|                  | Azacitadine (CC-486) + CHOP           | Previously untreated PTCL                                             | II    | 20 | CC-486 priming is given from D-6 to D0 before cycle 1, and D8-D21 during Cycles 1 to 5.                                                                                                                   | NCT03542266       |
|                  | Romidepsin + CHOP vs CHOP             | Patients with previously untreated PTCL                              | III   | 421| Experimental Arm: Ro-CHOP 21 with romidepsin 12 mg/m² given IV on D1 and D8 Q3 weeks for 6 cycles.                                                                                                         | NCT01796002       |
|                  | Romidepsin + lenalidomide             | Phase II study of romidepsin plus lenalidomide for patients with      | II    | 35 | Romidepsin on D1, 8, and 15, and lenalidomide PO QD on D1-21, every 28 days for up to 1 year in the absence of POD or unacceptable toxicity.                                                               | NCT02232516       |
| **Relapsed/      | Azacitadine vs. investigator’s choice  | Randomized phase 3 study for patients with R/R AITL                  | III   | 86 | Experimental arm: oral azacitadine 300 mg daily x 14 days of 28-day cycles (European patients) Oral azacitadine 200 mg daily x 12 days of 28-day cyclesControl: romidepsin 14 mg/m² on D1, 8, and 15 of 28-day cycle until POD, toxicity, or patient decision, or bendamustine 120 mg/m² on D1 and 2 of a 21-day cycle (during 6 cycles); or gemcitabine 1200 mg/m² on D1, 8, and 15 of a 28-day cycle (during 6 cycles) | NCT03593018       |
| refractory       |                                      |                                                                      |       |    |                                                                                                                                                                                                          |                    |
|                  | Pembrolizumab + romidepsin            | A phase I/II study of pembrolizumab (MK-3475) in combination         | I/I   | 39 | Romidepsin is given on D1 and D8. Pembrolizumab is given IV over 30 min on D1. Cycles repeat every 21 days for up to 36 cycles in the absence of POD or unacceptable toxicity.                                     | NCT03278782       |
|                  | Pembrolizumab + pralatrexate          | A phase 1/2 study of pembrolizumab plus pralatrexate for treatment   | I/I   | 40 | Dose escalation of pralatrexate + pembrolizumab. Pralatrexate is given IV over 3–5 min on D1 and 8 and pembrolizumab is given IV over 30 min on D1, repeat every 21 days.                                          | NCT03598998       |
|                  | Durvalumab ± lenalidomide             | A phase 1/2 trial of durvalumab given as a single agent or in        | I/I   | 62 | Arm 1: patients receive durvalumab IV over 1 h on D1. Arm 2: durvalumab + lenalidomide Patients receive durvalumab IV over 1 h on D1 and lenalidomide PO QD on D1-21 Treatment repeats every 28 days (± 3 days) for up to 13 courses in the absence of POD or unacceptable toxicity for both arms. | NCT03011814       |
|                  | Durvalumab ± pralatrexate, romidepsin,| Phase 1/2a study in patients with R/R PTCL                           | I/I   | 148| Arm A: durvalumab, 5-azacitadine (AZA)Arm B: durvalumab, pralatrexate, romidepsinArm C: durvalumab, romidepsinArm D: durvalumab, AZA                                                                 | NCT03161223       |
|                  | azacitadine                           |                                                                      |       |    |                                                                                                                                                                                                          |                    |
|                  | Pembrolizumab ± pralatrexate and      | Novel immuno-epigenetic-based platform for patients with PTCL and    | Iib   | 42 | Arm A: pembrolizumab + pralatrexate Pembrolizumab 200 mg is given IV D1 1 with pralatrexate 30 mg/m² IV D1, 8, and 15Arm B: pembrolizumab + pralatrexate + decitabine Pembrolizumab 200 mg is given IV D8 with pralatrexate 20 mg/m² IV D1, 8, and 15 and decitabine 10 mg/m² from D1 to 5Arm C: | NCT03240211       |
|                  | decitabine                            | CTCL: an international phase Ib study of pembrolizumab combined      |       |    | with decitabine and pralatrexate                                                                                                                                                                           |                    |
| Setting | Agent(s) | Study | Phase | Treatment |
|---------|----------|-------|-------|-----------|
| Avelumab PD-1 mAb | pembrolizumab + decitabine | pembrolizumab 200 mg is given IV and decitabine 20 mg/m² from D1 to 5. | II | Avelumab is given 10 mg/kg by IV infusion once every 2 weeks. A maximum of 8 cycles, each cycle is 28 days. NCT03046953 |
| BGB-A317 (tislelizumab)PD-1 mAb | Avelumab | A phase 2, open-label study of BGB-A317 in patients with R/R mature T- and NK-neoplasms | II | BGB A317 is given 200 mg IV on D1 of each 21-day cycle. NCT03493451 |
| Copanlisib + romidepsin | Copanlisib in combination with romidepsin in patients with R/R mature TCL | Dose escalation of copanlisib in combination with romidepsin | IB | NCT04233697 |
| YY-20394/P3K-δ inhibitor | A phase 1/IIA study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with PTCL | Dose escalation of pralatrexate and romidepsin. Patients receive both infusions D1 and D15 of each 28-day cycle. Phase II pralatrexate 25 mg/m² and romidepsin 12 mg/m² are given N once weekly on D1 and 15 on a 28-day cycle | I/II | NCT01947140 |
| DS-3201b inhibitor | A phase 1 multiple ascending dose study of DS-3201b in subjects with lymphomas | Dose escalation of DS-3201b | I | NCT02732275 |
| IDH2 (AG-221) | A phase 1/2, multicenter, open-label, dose-escalation study of AG-221 in subjects with advanced solid tumors, including glioma, and with AITL, that harbor an IDH2 mutation | AG-221 administered orally on every day of 28-day cycles until POD, intolerable toxicity, or the subject discontinues from the study treatment for other reasons. | I/II | NCT02273739 |
| Ruxolitinib | A phase 2 multicenter, investigator initiated study of oral ruxolitinib phosphate for the treatment of R/R diffuse large B cell and PTCL | Ruxolitinib is administered orally BID on D1–28 repeat courses Q28 days in the absence of POD or unacceptable toxicity. | II | NCT01431209 |
| AZD4205/JAK inhibitor | A phase VII, open-label, multicenter study to investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AZD4205 in patients with PTCL | AZD4205 will be administered orally as capsules in 2 dose cohorts. AZD4205 treatment will be continued until disease progression or intolerable adverse reactions | I/II | NCT04105010 |
| CerdulatinibSYK/JAK inhibitor | A phase 1/2A open-label, multi-dose, multi-center escalation and exploratory study of cerdulatinib (PRT062070) in patients with R/R CLL, SL, or B cell or T cell NHL | Phase I: Dose escalation or cerdulatinib starting at 15 mg dailyPhase II: Cerdulatinib administered at 30 mg PO BID for 28-day cycles. Six planned cohorts, cohort 2 also received rituximab IV 375 mg/m² | I/II | NCT02273739 |
| VenetoclaxBCL-2 inhibitor | Venetoclax (ABT-199) 800 mg is administered orally daily until POD, unacceptable toxicity, withdrawal of consent and/or investigator’s decision | Venetoclax (ABT-199) 800 mg is administered orally daily until POD, unacceptable toxicity, withdrawal of consent and/or investigator’s decision | II | NCT03552692 |
| Tipifarnib | An open-label phase II study of tipifarnib in subjects with relapsed or refractory peripheral T cell lymphoma | Tipifarnib 300 mg is given orally twice daily on D1–21 of 28-day treatment cycles | II | NCT02464228 |
| MEDI-570 mAb | Anti-ICOS monoclonal antibody MEDI-570 is given IV over 1–4 h on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of POD or unacceptable toxicity. | MEDI-570 is given IV over 1–4 h on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of POD or unacceptable toxicity. | I | NCT02520791 |
| DaratumumabCD38 mAb | A Phase II, open-label, multicenter trial of daratumumab in combination with gemcitabine, dexamethasone and cisplatin (D-GDP) | Induction phase: 4–6 courses (according to response after cycle 4 and to patient compliance) of D-GDP every 21 days as follows: | II | NCT04251065 |
| Setting | Agent(s) | Study | Phase | Treatment |
|---------|----------|-------|-------|-----------|
| ATLCAR.CD30 T cells | Phase II study of the administration of T lymphocytes expressing the CD30 chimeric antigen receptor (CAR) for R/R CD30+ PTCL | II | 20 | The cellular product consisting of ATLCAR.CD30 cells will be administered via IV injection over 5–10 min through either a peripheral or a central line. The volume of infusion will depend upon the concentration of the cells when frozen and the size of the subject. Administration to eligible subjects will occur within 2–14 days after completing lymphodepleting chemotherapy |
| AMF13 | A phase II open-label multicenter study to assess the efficacy and safety of AMF13 in patients with relapsed or refractory CD30-positive peripheral T cell lymphoma or transformed mycosis fungoides (REDIRECT) | II | 145 | AMF13 is given as weekly IV infusions of 200 mg |
| AMF13 | Bispecific antibody AMF13 combined with NK Cells for patients with recurrent or refractory CD30-positive Hodgkin or non-Hodgkin lymphomas | I | 30 | Patients receive standard of care fludarabine IV over 1 h and standard of care cyclophosphamide IV over 30–60 min on D-4 to -2, AMF13-NK IV over 4 h on D0, and then AMF13 IV over 4 h on D 7, 14, and 21. |
| AUTO4/TRBC1 targeted CAR-T cells | A single-arm, open-label, multi-center, phase I/II study evaluating the safety and clinical activity of AUTO4, a CART cell treatment targeting TRBC1, in patients with R/R TRBC1-positive selected T cell non-Hodgkin lymphoma | I/II | 55 | Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine) patients are treated with doses from 25 to 225 x 10^6 RQR8/aTRBC1 CAR T cells. Following phase 2 dose determination, patients will be treated with selected doses of RQR8/aTRBC1 CAR T cells (AUTO4). |
treatment with chidamide on days 1, 4, 8, and 11 every 21 days for 24 months maximum. Overall, 46.6% achieved CR/Cru with an additional 35.7% of patients achieving a PR, and PFS and OS at 12 months were 54.3% and 100%, respectively. Fifteen patients entered the consolidation phase. The combination was well tolerated with no AEs leading to discontinuation.

**Hypomethylating agents** In the frontline setting, a phase 2 multi-center trial evaluating the combination of oral azacitidine (CC486) plus CHOP as initial therapy for PTCL is ongoing, which prioritizes enrollment of PTCL patients with T follicular helper (TFH) phenotype and acquired genetic predisposition to chemosensitivity by hypomethylating agent (NCT03542266). Treatment program consists of priming of oral azacitidine for 7–14 days prior to each cycle of standard CHOP.

**Targeting tumor microenvironment** Lenalidomide in combination with CHOP-based chemotherapy was evaluated in 2 prospective phase 2 studies; both showed unexpectedly modest CR and PFS rates and high discontinuation rates due to substantial toxicities. The T cell Consortium study combined lenalidomide given 10 mg on days 1–10 with standard-dose CHOP (cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone) every 21-day cycle for 6 cycles followed by either upfront ASCT or lenalidomide maintenance (NCT02561273). The phase 2 efficacy analysis showed ITT ORR of 68% with CR of 48% and 1-year PFS and OS at 68% and 89%, respectively. Serious AEs (SAEs) and AEs included 5 treatment-related deaths and significant grade ≥3 cytopenias [76]. Lenalidomide (25 mg/day on days 1–14) plus CHOP was studied in AITL elderly patients by the French LYSa group (NCT01553786) [77]. ITT CR in the Len-CHOP study was 43.6%, with a 2-year PFS rate of 42.3% and a 2-year OS of 60.1%. Discontinuation rate was high at 28% due to toxicities and disease progression. Mutational analysis demonstrated TET2 mutations in 49 cases (77%), RHOA<sup>G17V</sup> mutations in 34 patients (53%), DNMT3A mutations in 20 (31%) patients, and IDH2 mutations in 14 (22%).

**Antifolate combination**

The antifolate agent pralatrexate was incorporated into the front-line setting alternating with CEOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in a phase II T cell Consortium trial [78]. Of 33 patients, 21 had PTCL—not otherwise specified (64%), 8 hadAITL (24%), and 4 hadALCL (12%). Fifty-two percent of patients achieved a CR. The 2-year PFS and OS were 39% and 60%, respectively. Overall, this approach did not improve outcomes compared to historical data using CHOP.

**Novel combination free of conventional chemotherapy**

Given the efficacy of single-agent immunomodulatory agent lenalidomide and HDAC inhibitor romidepsin in PTCL, the combination of immunomodulation and epigenetic manipulation has the potential synergy to target both tumor microenvironment and tumor cells. Based on a phase I/II trial evaluating the combination of lenalidomide and romidepsin at the MTD of romidepsin 14 mg/m² IV on days 1, 8, and 15 and lenalidomide 25 mg oral on days 1–21 of a 28-day cycle, which demonstrated ORR of 50% with acceptable safety profile in R/R PTCL [32], a multi-center phase 2 study is ongoing to assess the efficacy and safety of the romidepsin and lenalidomide combination in previously untreated PTCL patients who are not chemotherapy candidates (NCT02232516). Treatment is planned for up to 1 year in the absence of disease progression or unacceptable toxicities.

**Biomarker-driven consolidation and maintenance**

High-dose chemotherapy and autologous stem cell transplant (HDT-ASCT) for chemotherapy-sensitive disease is a therapeutic strategy for PTCL patients in first remission based on phase 2 studies. Three-year PFS with CHOP-based induction followed by HDT-ASCT was reported in the range of 36–44% in prospective studies [79, 80] and 58% in retrospective series [81, 82], signaling ongoing unmet needs for PFS improvement. Romidepsin maintenance therapy is being evaluated in a multi-center phase 2 study for patients in CR1/PR1 who have completed CHOP-based chemotherapy induction followed by HDT-ASCT with BEAM conditioning (NCT01908777). The primary objective is to assess 2-year PFS. The T cell Consortium frontline study with lenalidomide plus CHOP has a built-in design of consolidation with either upfront ASCT or lenalidomide maintenance (NCT02561273). Of the responding patients (68%; n = 30), 10 proceeded to lenalidomide maintenance. The 1-year estimated PFS and OS are 68% and 89%, respectively, and longer follow-up is needed to assess durability of lenalidomide maintenance treatment [76]. Maintenance strategy without HDT-ASCT was explored in the phase 1 frontline treatment of brentuximab vedotin (BV) plus CHOP combination. Patients received single-agent BV maintenance for 8–10 cycles following CHOP chemotherapy [68]. In the 26 patients (19 ALCL) treated with BV + CHP combination therapy and BV maintenance, ORR was 100% with CR of 92%, and 5-year PFS and OS were 52% and 80%, respectively, demonstrating durable remissions [69]. Ultimately, measurable improvement with consolidation and maintenance therapy will require confirmation from prospectively designed, randomized phase 3 studies.
Future directions
Emerging novel agents and combinations are in active clinical development which target the epigenome, proliferative signaling pathways, and the tumor microenvironment. Given the frequency of alterations in histone methylation and acetylation genes in PTCL, EZH2, which encodes the histone-lysine N-methyltransferase enzyme, has emerged as a potential therapeutic target. The EZH1/2 inhibitor DS-3201b has demonstrated in vitro anti-tumor activity in lymphoma cell lines and is being investigated in a phase I trial of patients with R/R PTCL (NCT02732275). The IDH2 inhibitor AG-221 is being studied in patients with advanced solid tumors or gliomas or R/R AITL who harbor these mutations (NCT02273739). An ongoing phase II trial is being conducted to explore the efficacy of the JAK1/2 inhibitor ruxolitinib in patients with R/R lymphoma, including PTCL (NCT01431209). Alternative JAK inhibitors are also being investigated including AZD4205 (NCT04105010). The dual SYK/JAK inhibitor cerdulatinib is under evaluation in a phase I/II trial in patients with BCL-2-positive TCL, including PTCL (NCT02520791). CD38 expression has been demonstrated in up to half of ENKTL [84], and the CD38 monoclonal antibody daratumumab has shown promising ORR of 35.7% in this population [85]. Daratumumab is being combined with gemcitabine, dexamethasone, and cisplatin in patients with CD38-positive PTCL (NCT04251065).

Several innovative techniques are being explored in PTCL. Chimeric antigen receptor T (CAR-T) cells directed against CD30 have been developed and are being explored in a phase II trial (NCT04083495) in patients with R/R CD30+ PTCL. AMF13, a bispecific antibody containing a binding site for CD30 and a second binding site for CD16A, the receptor responsible for NK cell activation, is being evaluated in R/R CTCL (NCT04101331). This molecule is also under clinical investigation in combination with NK cells in patients with R/R CD30+ lymphomas (NCT04074746). The T cell receptor β-chain (TCRB) is a pan-T cell antigen highly expressed on PTCL. CAR-T cells targeting TRBC1 are being studied in patients with TRBC1+ selected R/R PTCL (NCT03590574).

Conclusion
Peripheral T cell lymphomas are heterogeneous diseases, where relapse and refractory diseases are common. Recent advances in molecular and genomic profiling have provided unprecedented insight into disease pathogenesis driven by distinct cells of origins and molecular pathways. Delivering the most effective treatment tailored to underlying biology and therapeutic targets in the first-line and relapsed settings is poised to make the most enduring impact on patient’s survival outcome.

Abbreviations
AE: Adverse event; AITL: Angioimmunoblastic T cell lymphoma; ALK: Anaplastic lymphoma kinase; ATLL: Adult T cell leukemia/lymphoma; AZA: Azacitidine; BV: Brentuximab-vedotin; CAR-T: Chimeric antigen receptor T cell; CEP: Cyclophosphamide, etoposide, vincristine, prednisone; CHOEP: Cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone; CHOP: Cyclophosphamide, doxorubicin, vincristine, and prednisone; CMV: Cytomegalovirus; CR: Complete response; CRu: Complete response unconfirmed; CTCL: Cutaneous T cell lymphoma; DOR: Duration of response; EATL: Enteropathy-associated T cell lymphoma; EBV: Epstein-Barr virus; EFS: Event-free survival; ENKTL: Extranodal NK/T cell lymphoma; FTCL: Follicular T cell lymphoma; GEP: Gene expression profile; HDAC: Histone deacetylase; HSTL: Hepatosplenic T cell lymphoma; HTLV-1: Human T cell leukemia virus, type 1; MF: Mycosis fungoides; NGS: Next-generation sequencing; OR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; PI3K: Phosphoinositide 3-kinase; PjP: Pneumocystis jiroveci pneumonia; PR: Partial response; PTCL: Peripheral T cell lymphoma; PTCL-NOS: Peripheral T cell lymphoma, not otherwise specified; R/R: Relapsed/refractory; SAE: Serious adverse event; sALCL: Systemic anaplastic large cell lymphoma; SPTCL: Subcutaneous panniculitis-like T cell lymphoma; TFH: T follicular helper

Acknowledgements
None

Authors’ contributions
The authors each contributed to the concept design, data collection, and manuscript writing. EM created the figure. The authors read and approved the final manuscript.

Funding
Not applicable for this review.

Availability of data and materials
Not applicable for this review.

Ethics approval and consent to participate
Not applicable for this review.

Consent for publication
Not applicable for this review.

Competing interests
The authors have no competing interests to declare.
References

1. AVJ, Weisenberger DJ. International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology, findings and clinical outcomes. Journal of Clinical Oncology. 2008;26:41–24.

2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.

3. Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood. 2014;123:2915–23.

4. Wang T, Feldman AL, Wada DA, et al. GATA-3 expression identifies a high-risk subset of PTCL. NOS with distinct molecular and clinical features. Blood. 2014;123:3007–15.

5. Savage KU, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504.

6. Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

7. Lunning MA, Vose JM. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma. Blood. 2017;129:1085–102.

8. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (T<sub>fh</sub>) cells. Blood. 2007;109:4952–63.

9. de Leval L, Gauthier P. Cellular origin of T-cell lymphomas. Blood. 2014;123:2909–10.

10. W-Y A, Weisenberger DD. Intratumoral T cells: Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113:3931–7.

11. Cook LB, Fuji S, Hermine O, et al. Revised adult T-cell leukemia-lymphoma international consensus meeting report. J Clin Oncol. 2019;37:677–87.

12. Kataoka K, Nagata Y, Kitamura A, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:304–15.

13. Dürrkop H, Latza U, Hummel M, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68:421–7.

14. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10 and CD40- monomethyleauristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458–65.

15. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase I study. Journal of Clinical Oncology. 2012;30:2190–6.

16. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123:3095–100.

17. Xia MQ, Hale G, Lifrey MR, et al. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochemical Journal. 1993; 293:633–40.

18. Jiang L, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T-cell and NK cell malignancies: implications for alemtuzumab therapy. British Journal of Haematology. 2009;145:173–9.

19. Geissinger E, Bonnheur I, Roth S, et al. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leukemia & Lymphoma. 2009;50:1010–6.

20. Eniblad G, Hagberg H, Efranson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–4.

21. Dearden C. Management of prolymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2015:361–7.

22. Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120:538–51.

23. Dearden CE, Khot A, Else M, Hamblin M, Grand E, Roy A, Hewamana S, Manutes E, Catovsky D. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study pilotting the subcutaneous route. Blood. 2011;118(22):5799–802. 10.1182/ blood-2011-08-372651.

24. Wilcox RA, Mogamulizumab: 2 birds, 1 stone. Blood. 2015;125:1847–8.

25. Ishida T, Inagaki H, Utsunomiya A, et al. CC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clinical Cancer Research. 2004;10:5494–500.

26. Ishida T, Joh T, Ulke N, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. Journal of Clinical Oncology. 2012;30:887–42.

27. Ishida T, Utsunomiya A, Jo T, et al. Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies. Cancer Sci. 2017;108(10):2022–9. https://doi.org/10.1111/cas.13343.

28. Piekars RL, Robey RW, Zhan Z, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of deacetylase inhibition on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636–43.

29. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25:3109–15.

30. Coiffler B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology. 2012;30:631–6.

31. Coiffler B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/ refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. Journal of Hematology & Oncology. 2014;7:11.

32. Mehta-Shah N, Lunning MA, Boruchov AM, et al. A phase I/Ii trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: activity in T-cell lymphoma. Journal of Clinical Oncology. 2015;33:8521–2.

33. Mehta-Shah N, Moskowitz AJ, Lunning MA, et al. Phase I/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B- and T-cell lymphomas. Blood. 2017;130:821–1.

34. Amengual JE, Lichtenstein R, Lue J, et al. A phase 1 study of romidepsin and pralatrexate revealed marked activity in relapsed and refractory T-cell lymphoma. Blood. 2018;131:397–407.

35. O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. Journal of Clinical Oncology. 2015;33:2492–9.

36. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:766–71.

37. Shih AHI, Abed-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews Cancer. 2012;12:599.

38. Lennemann F, Dupuis J, Soubert P, et al. Treatment with S-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. Blood. 2018;131:407–10.

39. Dupuis J, Boye K, Martin N, et al. Expression of CXC13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derive from follicular helper T cells. The American Journal of Surgical Pathology. 2010;34:78–89.

40. Dupuis J, Boye K, Martin N, et al. Expression of CXC13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derive from follicular helper T cells. The American Journal of Surgical Pathology. 2006;30:490–4.

41. His ED, Said J, Macon WR, et al. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK- cell lymphomas: a North American PTCL study group project. The American Journal of Surgical Pathology. 2014;38:768–75.
antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157–63.

87. O’Connor OA, Özcan M, Jacobsen ED, et al. First multicenter, randomized phase 3 study in patients (Pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator’s choice (Lumiere trial; NCT01482962). Blood. 2015;126:341–1.

88. Kwong Y-L, Chan TSY, Tan D, et al. PD-1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase. Blood. 2017;129:2437–42.

89. d’Amore F, Leppä S, Gomes da Silva M. Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132:998.

90. Dupuis J, Morschhauser F, Ghesquières H, et al. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. The Lancet Haematology. 2017;2:e160–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.